Types segmentation categorizes antihemophilic factor offerings based on their manufacturing origin and molecular modifications, which directly influence pricing, supply chain complexity, and clinical adoption. Plasma‑derived concentrates, sourced from pooled human plasma, remain the legacy segment and represent roughly 20 % of the market; they are favored in regions with established blood‑bank infrastructures but are constrained by viral safety concerns and batch‑to‑batch variability. Recombinant full‑length products, produced via mammalian cell lines, dominate the market with an estimated 40 % share, reflecting their consistent purity and lower immunogenicity profile. Recombinant B‑domain‑deleted (BDD) variants, which retain functional activity while reducing molecular size, capture about 15 % of sales and are gaining traction due to improved manufacturing yields. Extended‑half‑life (EHL) recombinant molecules, engineered through Fc‑fusion or PEGylation, command roughly 20 % of the market, driven by reduced dosing frequency and enhanced patient adherence. Emerging gene‑therapy platforms, although classified separately in regulatory terms, are included here for completeness and account for the remaining 5 %, signaling a nascent shift toward curative approaches. This typology clarifies how each product class contributes to the overall Antihemophilic Factor segmentation landscape.
